AV-GBM-1 Patient-Specific Vaccines in Newly Diagnosed Primary Glioblastoma

Time: 4:45 pm
day: Day One

Details:

  • AV-GBM-1 product and manufacturing feasibility update
  • Phase 2 safety and survival data including exploratory subset analyses
  • Phase 3 clinical trial considerations and design

Speakers: